DLL3-targeted PET/CT scan for neuroendocrine cancer
Part of Cancer clinical trials.
This trial uses a special PET/CT scan that targets a substance called DLL3, found on some cancer cells, to see if doctors can better detect or monitor neuroendocrine carcinoma. It may help you and your doctor get clearer information about your cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with, or are suspected to have, neuroendocrine carcinoma (a cancer affecting certain hormone-making cells).
- Your blood levels of ProGRP or NSE (two markers used to track this cancer) are at least 3 times the normal upper limit.
- You are willing and able to provide written informed consent (or have a legal guardian do so).
- Your doctor expects you to live for more than 3 months, and you can follow the study schedule.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special PET/CT scan to look for a protein called DLL3 in small cell lung cancer. The scan may help doctors better see and understand the cancer. You may be able to join if you have suspected or confirmed small cell lung cancer and certain blood markers are high.
This trial tests a new drug called BL-M14D1 for people with certain types of advanced lung cancer or neuroendocrine tumors that have stopped responding to other treatments. It may be an option if your cancer has a specific marker called DLL3.
This trial tests a special injection (a radioactive tracer) that lights up PD-L1 in your tumors during a PET scan. It helps doctors see which tumors might respond to immunotherapy.
This study tests a new type of PET/CT scan that looks for a marker called DLL3 on neuroendocrine cancer cells. It aims to see if this scan finds tumors better than standard scans, which could help guide treatment.
This trial tests a special PET/CT imaging scan that may help doctors find where small cell lung cancer (and some related tumors) are in the body using a DLL3 target. It’s a Phase 1/2 study, mainly to see how well the scan detects tumors and guides care.
This trial tests a new drug called 177Lu-DTPA-SC16.56, which delivers radiation directly to cancer cells that have a specific marker called DLL3. It is for people with high-grade neuroendocrine lung or prostate cancer that has spread and gotten worse after at least one round of chemotherapy.
Hear when a new PET/CT trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.